Patents by Inventor Jun Takasaki
Jun Takasaki has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11018289Abstract: Disclosed is a thermoelectric generation system that generates electricity using waste heat from a steam condenser that exchanges heat with steam as cyclic water flows through a high temperature portion and a low temperature portion, the thermoelectric generation system including: a first hot-water discharge line used to discharge the cyclic water passing through the high temperature portion; a cyclic water circulation line through which the cyclic water from under water circulates; and a thermoelectric generation unit that generates electricity on the basis of a temperature difference between a temperature of the cyclic water flowing through the first hot-water discharge line and a temperature of the cyclic water flowing through the cyclic water circulation line.Type: GrantFiled: February 20, 2018Date of Patent: May 25, 2021Assignee: Kabushiki Kaisha ToshibaInventors: Keiji Sugi, Atsushi Wada, Tomoya Takeda, Jun Takasaki, Kenichi Shimano
-
Patent number: 10253105Abstract: The present application provides a bispecific antibody for preventing or treating an immune inflammatory disease by acting on both human TLR2 and human TLR4 to inhibit human TLR2- and human TLR4-mediated immune inflammatory effects. More specifically, the provided bispecific antibody is a bispecific antibody for human TLR2 and human TLR4, including a heavy chain variable region of an anti-human TLR2 antibody consisting of the amino acid sequence of amino acid numbers 1 to 120 of SEQ ID NO: 4; a light chain variable region of an anti-human TLR2 antibody consisting of the amino acid sequence of amino acid numbers 1 to 113 of SEQ ID NO: 6; a heavy chain variable region of an anti-human TLR4 antibody consisting of the amino acid sequence of amino acid numbers 491 to 609 of SEQ ID NO: 4; and a light chain variable region of an anti-human TLR4 antibody consisting of the amino acid sequence of amino acid numbers 625 to 732 of SEQ ID NO: 4.Type: GrantFiled: February 27, 2015Date of Patent: April 9, 2019Assignee: Astellas Pharma Inc.Inventors: Satoshi Takeuchi, Masahito Sato, Jotarou Suzuki, Shinji Soga, Jun Takasaki, Koji Aoyama, Chie Okuyama
-
Publication number: 20190088845Abstract: Disclosed is a thermoelectric generation system that generates electricity using waste heat from a steam condenser that exchanges heat with steam as cyclic water flows through a high temperature portion and a low temperature portion, the thermoelectric generation system including: a first hot-water discharge line used to discharge the cyclic water passing through the high temperature portion; a cyclic water circulation line through which the cyclic water from under water circulates; and a thermoelectric generation unit that generates electricity on the basis of a temperature difference between a temperature of the cyclic water flowing through the first hot-water discharge line and a temperature of the cyclic water flowing through the cyclic water circulation line.Type: ApplicationFiled: February 20, 2018Publication date: March 21, 2019Applicant: Kabushiki Kaisha ToshibaInventors: Keiji Sugi, Atsushi Wada, Tomoya Takeda, Jun Takasaki, Kenichi Shimano
-
Publication number: 20160355602Abstract: [Problem] To provide a bispecific antibody for preventing or treating an immune inflammatory disease by acting on both human TLR2 and human TLR4 to inhibit human TLR2- and human TLR4-mediated immune inflammatory effects. [Means for Solution] Provided is a bispecific antibody for human TLR2 and human TLR4, including a heavy chain variable region of an anti-human TLR2 antibody consisting of the amino acid sequence of amino acid numbers 1 to 120 of SEQ ID NO: 4; a light chain variable region of an anti-human TLR2 antibody consisting of the amino acid sequence of amino acid numbers 1 to 113 of SEQ ID NO: 6; a heavy chain variable region of an anti-human TLR4 antibody consisting of the amino acid sequence of amino acid numbers 491 to 609 of SEQ ID NO: 4; and a light chain variable region of an anti-human TLR4 antibody consisting of the amino acid sequence of amino acid numbers 625 to 732 of SEQ ID NO: 4.Type: ApplicationFiled: February 27, 2015Publication date: December 8, 2016Applicant: ASTELLAS PHARMA INC.Inventors: Satoshi TAKEUCHI, Masahito SATO, Jotarou SUZUKI, Shinji SOGA, Jun TAKASAKI, Koji AOYAMA, Chie OKUYAMA
-
Patent number: 9127055Abstract: Anti-human NGF antibodies are useful for treating pain.Type: GrantFiled: February 8, 2013Date of Patent: September 8, 2015Assignee: Astellas Pharma Inc.Inventors: Masazumi Kamohara, Hirotsugu Tanaka, Yukari Koya, Jun Takasaki, Atsuo Yonezawa, Eiji Yoshimi
-
Publication number: 20150218265Abstract: To provide an anti-human NGF antibody or an antigen-binding fragment thereof that is excellent in safety by reducing the risk of side effects such as effects on a fetus and thrombus formation while maintaining high neutralizing activity, and to provide means for preventing or treating various diseases in which human NGF is involved in the formation of pathological conditions, by using the antibody or the antibody-binding fragment thereof. An anti-human NGF antibody Fab? fragment comprising a heavy-chain variable region consisting of an amino acid sequence shown by SEQ ID NO:6 and a light-chain variable region consisting of an amino acid sequence shown by SEQ ID NO:4.Type: ApplicationFiled: January 14, 2015Publication date: August 6, 2015Applicant: Astellas Pharma Inc.Inventors: Masazumi Kamohara, Hirotsugu Tanaka, Yukari Koya, Jun Takasaki, Atsuo Yonezawa, Eiji Yoshimi
-
Patent number: 8986952Abstract: [Task] To provide an anti-human NGF antibody or an antigen-binding fragment thereof that is excellent in safety by reducing the risk of side effects such as effects on a fetus and thrombus formation while maintaining high neutralizing activity, and to provide means for preventing or treating various diseases in which human NGF is involved in the formation of pathological conditions, by using the antibody or the antibody-binding fragment thereof. [Means for Resolution] An anti-human NGF antibody Fab? fragment comprising a heavy-chain variable region consisting of an amino acid sequence shown by SEQ ID NO:6 and a light-chain variable region consisting of an amino acid sequence shown by SEQ ID NO:4.Type: GrantFiled: August 10, 2012Date of Patent: March 24, 2015Assignee: Astellas Pharma Inc.Inventors: Masazumi Kamohara, Hirotsugu Tanaka, Yukari Koya, Jun Takasaki, Atsuo Yonezawa, Eiji Yoshimi
-
Publication number: 20140227287Abstract: [Task] To provide an anti-human NGF antibody or an antigen-binding fragment thereof that is excellent in safety by reducing the risk of side effects such as the effects on a fetus, thrombus formation, and joint-related adverse events such as RPOA while maintaining high neutralizing activity, and to provide means for preventing or treating various diseases in which human NGF is involved in the formation of pathological conditions, by using the antibody or the antibody-binding fragment thereof. [Means for Resolution] An anti-human NGF antibody Fab? fragment comprising a heavy-chain variable region consisting of an amino acid sequence represented by SEQ ID NO:6 and a light-chain variable region consisting of an amino acid sequence represented by SEQ ID NO:4.Type: ApplicationFiled: February 8, 2013Publication date: August 14, 2014Applicant: Astellas Pharma Inc.Inventors: Masazumi KAMOHARA, Hirotsugu Tanaka, Yukari Koya, Jun Takasaki, Atsuo Yonezawa, Eiji Yoshimi
-
Publication number: 20140155582Abstract: [Task] To provide an anti-human NGF antibody or an antigen-binding fragment thereof that is excellent in safety by reducing the risk of side effects such as effects on a fetus and thrombus formation while maintaining high neutralizing activity, and to provide means for preventing or treating various diseases in which human NGF is involved in the formation of pathological conditions, by using the antibody or the antibody-binding fragment thereof. [Means for Resolution] An anti-human NGF antibody Fab? fragment comprising a heavy-chain variable region consisting of an amino acid sequence shown by SEQ ID NO:6 and a light-chain variable region consisting of an amino acid sequence shown by SEQ ID NO:4.Type: ApplicationFiled: August 10, 2012Publication date: June 5, 2014Applicant: Astellas Pharma Inc.Inventors: Masazumi Kamohara, Hirotsugu Tanaka, Yukari Koya, Jun Takasaki, Atsuo Yonezawa, Eiji Yoshimi
-
Patent number: 8629126Abstract: Disclosed are quinolone derivatives characterized in that these have lower alkyl, cycloalkyl or the like at the 1-position; —N(R0)C(O)-lower alkylene-CO2R0, lower alkylene-CO2R0, lower alkenylene-CO2R0, —O-lower alkylene-CO2R0, —O-(lower alkylene which may be substituted with —CO2R0)-aryl or —O-lower alkenylene-CO2R0 (wherein R0 is H or lower alkyl) at the 3-position; halogen at the 6-position; and amino group substituted with a substituent group having a ring structure at the 7-position, respectively, or pharmaceutically acceptable salts thereof, has excellent P2Y12 inhibitory activity. The quinolone derivatives have excellent platelet aggregation inhibitory activity. A method of using the compounds is also disclosed.Type: GrantFiled: February 2, 2012Date of Patent: January 14, 2014Assignee: Astellas Pharma Inc.Inventors: Yuji Koga, Takao Okuda, Susumu Watanuki, Takashi Kamikubo, Fukushi Hirayama, Hiroyuki Moritomo, Jiro Fujiyasu, Michihito Kageyama, Toshio Uemura, Jun Takasaki
-
Publication number: 20120136025Abstract: Disclosed are quinolone derivatives characterized in that these have lower alkyl, cycloalkyl or the like at the 1-position; —N(R0)C(O)-lower alkylene-CO2R0, lower alkylene-CO2R0, lower alkenylene-CO2R0, —O-lower alkylene-CO2R0, —O-(lower alkylene which may be substituted with —CO2R0)-aryl or —O-lower alkenylene-CO2R0 (wherein R0 is H or lower alkyl) at the 3-position; halogen at the 6-position; and amino group substituted with a substituent group having a ring structure at the 7-position, respectively, or pharmaceutically acceptable salts thereof, has excellent P2Y12 inhibitory activity. The quinolone derivatives have excellent platelet aggregation inhibitory activity. A method of using the compounds is also disclosed.Type: ApplicationFiled: February 2, 2012Publication date: May 31, 2012Applicant: ASTELLAS PHARMA INC.Inventors: Yuji KOGA, Takao OKUDA, Susumu WATANUKI, Takashi KAMIKUBO, Fukushi HIRAYAMA, Hiroyuki MORITOMO, Jiro FUJIYASU, Michihito KAGEYAMA, Toshio UEMURA, Jun TAKASAKI
-
Patent number: 8133882Abstract: Provided are quinolone derivatives having a lower alkyl or cycloalkyl at the 1-position; —N(R0)C(O)-lower alkylene-CO2R0, lower alkylene-CO2R0, lower alkenylene-CO2R0, —O-lower alkylene-CO2R0, —O-(lower alkylene which may be substituted with —CO2R0)-aryl or —O-lower alkenylene-CO2R0 (wherein R0 is H or lower alkyl) at the 3-position; halogen at the 6-position; and amino group substituted with a substituent group having a ring structure at the 7-position, respectively, or pharmaceutically acceptable salts thereof. Pharmaceutical composition containing the quinolone derivatives and methods of using the compositions are provided.Type: GrantFiled: March 14, 2007Date of Patent: March 13, 2012Assignee: Astellas Pharma IncInventors: Yuji Koga, Takao Okuda, Susumu Watanuki, Takashi Kamikubo, Fukushi Hirayama, Hiroyuki Moritomo, Jiro Fujiyasu, Michihito Kageyama, Toshio Uemura, Jun Takasaki
-
Publication number: 20110207655Abstract: [Problem]A compound useful for the prevention and/or treatment of chronic obstructive pulmonary disease (COPD) or asthma, and a pharmaceutical composition containing the compound as an active ingredient are provided. [Means for Solution]The present inventors have made extensive studies on the pharmacological actions of naturally fermented materials, and as a result, they have found that a cyclic depsipeptide compound derived from a soil bacterium belonging to the genus Chromobacterium which is collected in Okutama-machi, Tokyo has both an inhibitory action on airway contraction and an inhibitory action on airway inflammation, and thus, is useful as an agent for preventing or treating COPD or asthma, thereby completing the present invention.Type: ApplicationFiled: October 23, 2009Publication date: August 25, 2011Applicant: Astellas Pharma Inc.Inventors: Susumu Tsujimoto, Masatoshi Taniguchi, Yoshitaka Hirayama, Jun Takasaki, Tomihisa Kawasaki, Kazutoshi Sakamoto, Shinya Nishiwaki, Yukihiro Kitanaga
-
Patent number: 7879878Abstract: A platelet aggregation inhibitor comprising a quinolone derivative or a pharmaceutically acceptable salt thereof as an active ingredient, and a novel quinolone derivative or a pharmaceutically acceptable salt thereof useful as a platelet aggregation inhibitor.Type: GrantFiled: December 31, 2008Date of Patent: February 1, 2011Assignee: Astellas Pharma Inc.Inventors: Susumu Watanuki, Yuji Koga, Hiroyuki Moritomo, Issei Tsukamoto, Daisuke Kaga, Takao Okuda, Fukushi Hirayama, Yumiko Moritani, Jun Takasaki
-
Publication number: 20100144677Abstract: A convenient screening tool and a convenient screening method for obtaining an agent for treating diabetes, a pharmaceutical composition for treating diabetes, and a process for manufacturing the pharmaceutical composition are disclosed. The screening tool is a G protein-coupled receptor, a variation functionally equivalent thereto, or a homologous polypeptide thereof which promotes insulin secretion under a high glucose concentration by activation, or cells transformed with an expression vector comprising a polynucleotide encoding the above polypeptide and expressing the polypeptide.Type: ApplicationFiled: November 19, 2009Publication date: June 10, 2010Applicant: ASTELLAS PHARMA, INC.Inventors: Takahide Ohishi, Jun Takasaki, Mitsuyuki Matsumoto, Tetsu Saito, Masazumi Kamohara, Takatoshi Soga, Shigeru Yoshida, Yoshitaka Ueda
-
Patent number: 7662775Abstract: The invention relates to a convenient screening tool for identifying an agent for treating diabetes. The screening tool is a G protein-coupled receptor, a variant of the G protein-coupled receptor, or a homolog of the G protein-coupled receptor, which promotes insulin secretion under a high glucose concentration by activation. The invention also relates to cells transformed with an expression vector comprising a polynucleotide encoding and expressing the screening tool. The invention provides a convenient screening method for identifying an agent for treating diabetes, pharmaceutical compositions comprising the agent, and a process for manufacturing the pharmaceutical composition.Type: GrantFiled: October 29, 2004Date of Patent: February 16, 2010Assignee: Astellas Pharma Inc.Inventors: Takahide Ohishi, Jun Takasaki, Mitsuyuki Matsumoto, Tetsu Saito, Masazumi Kamohara, Takatoshi Soga
-
Publication number: 20090197834Abstract: [Problem] To provide a compound having excellent platelet aggregation inhibitory activity. [Means for Resolution] It was found that quinolone derivatives characterized in that these have lower alkyl, cycloalkyl or the like at the 1-position; —N(R0)C(O)-lower alkylene-CO2R0, lower alkylene-CO2R0, lower alkenylene-CO2R0, —O-lower alkylene-CO2R0, —O-(lower alkylene which may be substituted with —CO2R0)-aryl or —O-lower alkenylene-CO2R0 (wherein R0 is H or lower alkyl) at the 3-position; halogen at the 6-position; and amino group substituted with a substituent group having a ring structure at the 7-position, respectively, or pharmaceutically acceptable salts thereof, has excellent P2Y12 inhibitory activity. In addition, it was confirmed that these quinolone derivatives also have excellent platelet aggregation inhibitory activity. Based on the above, these quinolone derivatives or pharmaceutically acceptable salts thereof are useful as platelet aggregation inhibitors.Type: ApplicationFiled: March 14, 2007Publication date: August 6, 2009Applicant: ASTELLAS PHARMA INC.Inventors: Yuji Koga, Takao Okuda, Susumu Watanuki, Takashi Kamikubo, Fukushi Hirayama, Hiroyuki Moritomo, Jiro Fujiyasu, Michihito Kageyama, Toshio Uemura, Jun Takasaki
-
Publication number: 20090124617Abstract: A platelet aggregation inhibitor comprising a quinolone derivative or a pharmaceutically acceptable salt thereof as an active ingredient, and a novel quinolone derivative or a pharmaceutically acceptable salt thereof useful as a platelet aggregation inhibitor.Type: ApplicationFiled: December 31, 2008Publication date: May 14, 2009Applicant: ASTELLAS PHARMA INC.Inventors: Susumu WATANUKI, Yuji KOGA, Hiroyuki MORITOMO, Issei TSUKAMOTO, Daisuke KAGA, Takao OKUDA, Fukushi HIRAYAMA, Yumiko MORITANI, Jun TAKASAKI
-
Patent number: 7488739Abstract: A platelet aggregation inhibitor comprising a quinolone derivative or a pharmaceutically acceptable salt thereof as an active ingredient, and a novel quinolone derivative or a pharmaceutically acceptable salt thereof useful as a platelet aggregation inhibitor.Type: GrantFiled: July 22, 2004Date of Patent: February 10, 2009Assignee: Astellas Pharma Inc.Inventors: Susumu Watanuki, Yuji Koga, Hiroyuki Moritomo, Issei Tsukamoto, Daisuke Kaga, Takao Okuda, Fukushi Hirayama, Yumiko Moritani, Jun Takasaki
-
Patent number: 7405051Abstract: A screening tool for an antiplatelet agent wherein the tool is a human ADP receptor P2TAC protein, a variation functionally equivalent thereto, or a homologous protein thereof, and a screening tool for an antiplatelet agent wherein the tool is a transformant which is transformed with an expression vector comprising a DNA encoding the protein and is expressing the polypeptide are disclosed. Further, a method for detecting an ADP receptor P2TAC ligand, antagonist, or agonist by using the screening tool for an antiplatelet agent, and a method for screening an antiplatelet agent by the detecting method are disclosed.Type: GrantFiled: October 31, 2001Date of Patent: July 29, 2008Assignee: Astellas Pharma Inc.Inventors: Jun Takasaki, Mitsuyuki Matsumoto, Masazumi Kamohara, Tetsu Saito, Takahide Ohishi, Takatoshi Soga